Grandfield & Dodd LLC Trims Holdings in Sanofi $SNY

Grandfield & Dodd LLC reduced its holdings in shares of Sanofi (NASDAQ:SNY) by 3.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 381,365 shares of the company’s stock after selling 12,512 shares during the quarter. Grandfield & Dodd LLC’s holdings in Sanofi were worth $18,481,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. CSM Advisors LLC bought a new position in Sanofi during the third quarter worth $18,244,000. Caprock Group LLC bought a new position in Sanofi during the third quarter worth $1,347,000. Natixis Advisors LLC lifted its stake in Sanofi by 11.8% during the third quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company’s stock worth $146,952,000 after purchasing an additional 327,569 shares during the last quarter. Assetmark Inc. lifted its stake in Sanofi by 25.0% during the third quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock worth $16,859,000 after purchasing an additional 71,356 shares during the last quarter. Finally, XY Capital Ltd bought a new position in Sanofi during the third quarter worth $1,603,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SNY has been the topic of several research analyst reports. Morgan Stanley set a $52.00 price objective on Sanofi in a research note on Friday, May 1st. Wall Street Zen cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Citigroup restated a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Finally, Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $51.00.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $43.67 on Friday. Sanofi has a 1-year low of $42.33 and a 1-year high of $52.68. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. The business’s fifty day moving average price is $45.62 and its two-hundred day moving average price is $47.04. The firm has a market capitalization of $106.51 billion, a PE ratio of 12.20, a P/E/G ratio of 1.08 and a beta of 0.35.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th will be given a $2.4225 dividend. This is a boost from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. The ex-dividend date of this dividend is Monday, May 4th. Sanofi’s dividend payout ratio is 49.16%.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.